GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » HeraMED Ltd (FRA:1I4) » Definitions » Land And Improvements

HeraMED (FRA:1I4) Land And Improvements : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is HeraMED Land And Improvements?

HeraMED's land and improvements for the quarter that ended in Dec. 2024 was €0.00 Mil.


HeraMED Land And Improvements Historical Data

The historical data trend for HeraMED's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeraMED Land And Improvements Chart

HeraMED Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Land And Improvements
Get a 7-Day Free Trial - - - - -

HeraMED Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

HeraMED Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


HeraMED Business Description

Traded in Other Exchanges
Address
201, 697 Burke Road, Suite 4, Camberwell, VIC, AUS, 3124
HeraMED Ltd is engaged in developing, connected pregnancy monitoring solutions for home and professional use. It has developed a foetal heartbeat monitor called HeraBEAT which is a medical-grade, clinically-validated, smart and connected Ultrasound Foetal Doppler device predominantly for use by an expectant mother to self-monitor her foetus' heart rate (FHR). It is also focused on the commercialization and deployment of its HeraCARE pregnancy monitoring solution. Geographically, the company generates a majority of its revenue from the United States of America followed by Australia and Israel.

HeraMED Headlines

No Headlines